English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Anle138b partly ameliorates motor deficits despite failure of neuroprotection in a model of advanced multiple system atrophy.

Fellner, L., Kuzdas-Wood, D., Levin, J., Ryazanov, S., Leonov, A., Griesinger, C., et al. (2016). Anle138b partly ameliorates motor deficits despite failure of neuroprotection in a model of advanced multiple system atrophy. Frontiers in Neuroscience, 10: 99. doi:10.3389/fnins.2016.00099.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-002A-1A5B-2 Version Permalink: http://hdl.handle.net/11858/00-001M-0000-002A-1A5E-B
Genre: Journal Article

Files

show Files
hide Files
:
2261917.pdf (Publisher version), 6MB
Name:
2261917.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
-

Locators

show

Creators

show
hide
 Creators:
Fellner, L., Author
Kuzdas-Wood, D., Author
Levin, J., Author
Ryazanov, S.1, Author              
Leonov, A.1, Author              
Griesinger, C.1, Author              
Giese, A., Author
Wenning, G. K., Author
Stefanova, N., Author
Affiliations:
1Department of NMR Based Structural Biology, MPI for biophysical chemistry, Max Planck Society, ou_578567              

Content

show
hide
Free keywords: Anle138b; alpha-synuclein; multiple system atrophy; glial cytoplasmic inclusions; 3-nitropropionic acid
 Abstract: The neurodegenerative disorder multiple system atrophy (MSA) is characterized by autonomic failure, cerebellar ataxia and parkinsonism in any combination associated with predominantly oligodendroglial alpha-synuclein (alpha-syn) aggregates (glial cytoplasmic inclusions = GCls). To date, there is no effective disease modifying therapy. Previous experiments have shown that the aggregation inhibitor anle138b reduces neurodegeneration, as well as behavioral deficits in both transgenic and toxin mouse models of Parkinson's disease (PD). Here we analyzed whether anle138b improves motor skills and reduces neuronal loss, as well as oligodendroglial alpha-syn aggregation in the PLP-alpha-syn transgenic mouse challenged with the mitochondria' toxin 3-nitropropionic acid (3-NP) to model full-blown MSA. Following 1 month of treatment with anle138b, MSA mice showed signs of motor improvement affecting stride length, but not pole, grip strength, and beam test performance. Loss of dopaminergic nigral neurons and Purkinje cells was not attenuated and GCI density remained unchanged. These data suggest that the pathology in transgenic PLP-alpha-syn mice receiving 3-NP might be too advanced to detect significant effects of anle138b treatment on neuronal loss and intracytoplasmic alpha-syn inclusion bodies. However, the partial motor amelioration may indicate potential efficacy of anle138b treatment that may be mediated by its actions on alpha-syn oligomers or may reflect improvement of neuronal dysfunction in neural at risk populations. Further studies are required to address the efficacy of anle138b in transgenic alpha-syn models of early-stage MSA and in the absence of additional toxin application.

Details

show
hide
Language(s): eng - English
 Dates: 2016-03-10
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: Peer
 Identifiers: DOI: 10.3389/fnins.2016.00099
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Frontiers in Neuroscience
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: 9 Volume / Issue: 10 Sequence Number: 99 Start / End Page: - Identifier: -